Key Points
- Patients with mCRC with a left-sided primary tumor carry a better prognosis than patients with tumors originating on the right side.
- Adding cetuximab to chemotherapy improves outcomes for patients with left-sided tumors, but not for those with right-sided ones.
- Side of origin should be considered when deciding on therapeutic regimens for patients with mCRC.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2s3jh5Y
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου